The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests

BackgroundThe fight against the current coronavirus disease 2019 (COVID-19) pandemic has created a huge demand of biotechnological, pharmaceutical, research and sanitary materials at unprecedented scales. One of the most urgent demands affects the diagnostic tests. The growing need for rapid and acc...

Full description

Bibliographic Details
Main Authors: Laura Williams, Silvia Jurado, Francisco Llorente, Alberto Romualdo, Sara González, Ana Saconne, Isabel Bronchalo, Mercedes Martínez-Cortes, Beatriz Pérez-Gómez, Fernando Ponz, Miguel Ángel Jiménez-Clavero, Pablo Lunello
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Plant Science
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fpls.2021.699665/full
id doaj-c0acbdd268a64b82ba169d52c3676c25
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Laura Williams
Silvia Jurado
Francisco Llorente
Alberto Romualdo
Sara González
Ana Saconne
Isabel Bronchalo
Mercedes Martínez-Cortes
Beatriz Pérez-Gómez
Beatriz Pérez-Gómez
Fernando Ponz
Miguel Ángel Jiménez-Clavero
Miguel Ángel Jiménez-Clavero
Pablo Lunello
spellingShingle Laura Williams
Silvia Jurado
Francisco Llorente
Alberto Romualdo
Sara González
Ana Saconne
Isabel Bronchalo
Mercedes Martínez-Cortes
Beatriz Pérez-Gómez
Beatriz Pérez-Gómez
Fernando Ponz
Miguel Ángel Jiménez-Clavero
Miguel Ángel Jiménez-Clavero
Pablo Lunello
The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests
Frontiers in Plant Science
COVID-19
SARS CoV-2 nucleocapsid protein
biofactories
plant expression
molecular farming
ELISA coronavirus
author_facet Laura Williams
Silvia Jurado
Francisco Llorente
Alberto Romualdo
Sara González
Ana Saconne
Isabel Bronchalo
Mercedes Martínez-Cortes
Beatriz Pérez-Gómez
Beatriz Pérez-Gómez
Fernando Ponz
Miguel Ángel Jiménez-Clavero
Miguel Ángel Jiménez-Clavero
Pablo Lunello
author_sort Laura Williams
title The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests
title_short The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests
title_full The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests
title_fullStr The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests
title_full_unstemmed The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests
title_sort c-terminal half of sars-cov-2 nucleocapsid protein, industrially produced in plants, is valid as antigen in covid-19 serological tests
publisher Frontiers Media S.A.
series Frontiers in Plant Science
issn 1664-462X
publishDate 2021-07-01
description BackgroundThe fight against the current coronavirus disease 2019 (COVID-19) pandemic has created a huge demand of biotechnological, pharmaceutical, research and sanitary materials at unprecedented scales. One of the most urgent demands affects the diagnostic tests. The growing need for rapid and accurate laboratory diagnostic tests requires the development of biotechnological processes aimed at producing reagents able to cope with this demand in a scalable, cost-effective manner, with rapid turnaround times. This is particularly applicable to the antigens employed in serological tests. Recombinant protein expression using plants as biofactories is particularly suitable for mass production of protein antigens useful in serological diagnosis, with a neat advantage in economic terms.MethodsWe expressed a large portion of the nucleoprotein (N) derived from SARS-CoV-2 in Nicotiana benthamiana plants. After purification, the recombinant N protein obtained was used to develop an indirect enzyme-linked immunosorbent assay (ELISA) for detection of antibodies to SARS-CoV-2 in human sera. To validate the ELISA, a panel of 416 sera from exposed personnel at essential services in Madrid City Council were tested, and the results compared to those obtained by another ELISA, already validated, used as reference. Furthermore, a subset of samples for which RT-PCR results were available were used to confirm sensitivity and specificity of the test.ResultsThe performance of the N protein expressed in plants as antigen in serologic test for SARS-CoV-2 antibody detection was shown to be highly satisfactory, with calculated diagnostic sensitivity of 96.41% (95% CI: 93.05–98.44) and diagnostic specificity of 96.37 (95% CI: 93.05–98.44) as compared to the reference ELISA, with a kappa (K) value of 0.928 (95% CI:0.892–0.964). Furthermore, the ELISA developed with plant-derived N antigen detected SARS-CoV-2 antibodies in 84 out of 93 sera from individuals showing RT-PCR positive results (86/93 for the reference ELISA).ConclusionThis study demonstrates that the N protein part derived from SARS-CoV-2 expressed in plants performs as a perfectly valid antigen for use in COVID-19 diagnosis. Furthermore, our results support the use of this plant platform for expression of recombinant proteins as reagents for COVID-19 diagnosis. This platform stands out as a convenient and advantageous production system, fit-for-purpose to cope with the current demand of this type of biologicals in a cost-effective manner, making diagnostic kits more affordable.
topic COVID-19
SARS CoV-2 nucleocapsid protein
biofactories
plant expression
molecular farming
ELISA coronavirus
url https://www.frontiersin.org/articles/10.3389/fpls.2021.699665/full
work_keys_str_mv AT laurawilliams thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT silviajurado thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT franciscollorente thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT albertoromualdo thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT saragonzalez thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT anasaconne thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT isabelbronchalo thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT mercedesmartinezcortes thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT beatrizperezgomez thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT beatrizperezgomez thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT fernandoponz thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT miguelangeljimenezclavero thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT miguelangeljimenezclavero thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT pablolunello thecterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT laurawilliams cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT silviajurado cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT franciscollorente cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT albertoromualdo cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT saragonzalez cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT anasaconne cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT isabelbronchalo cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT mercedesmartinezcortes cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT beatrizperezgomez cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT beatrizperezgomez cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT fernandoponz cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT miguelangeljimenezclavero cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT miguelangeljimenezclavero cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
AT pablolunello cterminalhalfofsarscov2nucleocapsidproteinindustriallyproducedinplantsisvalidasantigenincovid19serologicaltests
_version_ 1721279535819784192
spelling doaj-c0acbdd268a64b82ba169d52c3676c252021-07-27T15:04:27ZengFrontiers Media S.A.Frontiers in Plant Science1664-462X2021-07-011210.3389/fpls.2021.699665699665The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological TestsLaura Williams0Silvia Jurado1Francisco Llorente2Alberto Romualdo3Sara González4Ana Saconne5Isabel Bronchalo6Mercedes Martínez-Cortes7Beatriz Pérez-Gómez8Beatriz Pérez-Gómez9Fernando Ponz10Miguel Ángel Jiménez-Clavero11Miguel Ángel Jiménez-Clavero12Pablo Lunello13Agrenvec S.L., Madrid, SpainAgrenvec S.L., Madrid, SpainCentro de Investigación en Sanidad Animal (CISA), Centro Nacional Instituto de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC), Valdeolmos, SpainAgrenvec S.L., Madrid, SpainAgrenvec S.L., Madrid, SpainAgrenvec S.L., Madrid, SpainAgrenvec S.L., Madrid, SpainMadrid Salud: Public Health Services of Madrid City Council, Madrid, SpainNational Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, SpainConsortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, SpainCentro de Biotecnología y Genómica de Plantas, Universidad Politécnica de Madrid-Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (CBGP, UPM-INIA, CSIC), Madrid, SpainCentro de Investigación en Sanidad Animal (CISA), Centro Nacional Instituto de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC), Valdeolmos, SpainConsortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, SpainAgrenvec S.L., Madrid, SpainBackgroundThe fight against the current coronavirus disease 2019 (COVID-19) pandemic has created a huge demand of biotechnological, pharmaceutical, research and sanitary materials at unprecedented scales. One of the most urgent demands affects the diagnostic tests. The growing need for rapid and accurate laboratory diagnostic tests requires the development of biotechnological processes aimed at producing reagents able to cope with this demand in a scalable, cost-effective manner, with rapid turnaround times. This is particularly applicable to the antigens employed in serological tests. Recombinant protein expression using plants as biofactories is particularly suitable for mass production of protein antigens useful in serological diagnosis, with a neat advantage in economic terms.MethodsWe expressed a large portion of the nucleoprotein (N) derived from SARS-CoV-2 in Nicotiana benthamiana plants. After purification, the recombinant N protein obtained was used to develop an indirect enzyme-linked immunosorbent assay (ELISA) for detection of antibodies to SARS-CoV-2 in human sera. To validate the ELISA, a panel of 416 sera from exposed personnel at essential services in Madrid City Council were tested, and the results compared to those obtained by another ELISA, already validated, used as reference. Furthermore, a subset of samples for which RT-PCR results were available were used to confirm sensitivity and specificity of the test.ResultsThe performance of the N protein expressed in plants as antigen in serologic test for SARS-CoV-2 antibody detection was shown to be highly satisfactory, with calculated diagnostic sensitivity of 96.41% (95% CI: 93.05–98.44) and diagnostic specificity of 96.37 (95% CI: 93.05–98.44) as compared to the reference ELISA, with a kappa (K) value of 0.928 (95% CI:0.892–0.964). Furthermore, the ELISA developed with plant-derived N antigen detected SARS-CoV-2 antibodies in 84 out of 93 sera from individuals showing RT-PCR positive results (86/93 for the reference ELISA).ConclusionThis study demonstrates that the N protein part derived from SARS-CoV-2 expressed in plants performs as a perfectly valid antigen for use in COVID-19 diagnosis. Furthermore, our results support the use of this plant platform for expression of recombinant proteins as reagents for COVID-19 diagnosis. This platform stands out as a convenient and advantageous production system, fit-for-purpose to cope with the current demand of this type of biologicals in a cost-effective manner, making diagnostic kits more affordable.https://www.frontiersin.org/articles/10.3389/fpls.2021.699665/fullCOVID-19SARS CoV-2 nucleocapsid proteinbiofactoriesplant expressionmolecular farmingELISA coronavirus